Clinical Use of Cinacalcet in MEN1 Hyperparathyroidism

Table 1

Summary of clinical details, demographics and biochemical data for the cohort studied. This table summarises the details regarding the diagnosis of MEN1, parathyroid disease, and biochemical data pre- and post commencement of cinacalcet. A significant reduction in serum corrected calcium and serum PTH was determined. Bracketed () results indicate PTH levels taken 4 hours post dose.

Pt	Age/ M/F	Diagnoses	Prev PTH surgery (No)	Number Glands removed	Complications			Serum corr-Calcium mmol/L		Serum PTH pmol/L
					Low BMD	Renal Calculi	Low GFR	Pre	Post	Pre	Post
1	35; F	PTH, PRL,; NF Islet cell	0	n/a	N	N	N	2.62	2.26	35.8	29.4; (41.7)
2	40; M	PTH, PRL	1	3	N	Y	N	2.64	2.54	17.6	12.4
3	58; M	PTH,; Gastrinoma	2	4	Y	N	Y	2.81	2.13	14.1	6.8; (12.8)
4	52; M	PTH,; NF Islet cell	1	3	Y	N	N	2.76	2.21	4.8	2.8; (3.1)
5	53; F	PTH, NFPA,; Gastrinoma	4	2	Y	Y	Y	2.74	2.51	9.8	7.7; (3.8)
6	26; F	PTH,; NF Islet cell	1	3	N	N	N	2.84	2.44	7.3	2.4; (2.4)
7	46; F	PTH,; Gastrinoma	0	n/a	Y	Y	Y	2.91	2.30	36.5	11.7
8	38; F	PTH, PRL,; Gastrinoma	1	2	Y	Y	N	2.75	2.40	21.5	18.6

Key: M: Male; F: female; PTH: Hyperparathyroidism; PRL: prolactinoma; NF Islet Cell: Non functioning Islet Cell tumour; BMD: Bone Mineral Density; n/a not applicable; No: number; GFR:Glomerular Filtration Rate.